Group 1 - Sanwang Communication plans to repurchase shares worth 20-40 million yuan for employee stock incentive plans [1] - Ankrui reported a net profit of 192 million yuan for the first three quarters, a year-on-year increase of 21.31% [1] - Taishan Petroleum's net profit for the first three quarters reached 113 million yuan, up 112.32% year-on-year [1] - Zhejiang Xiantong achieved a net profit of 152 million yuan for the first three quarters, a 17.4% increase year-on-year [1] Group 2 - Xuanji Information reported a net loss of 173 million yuan for the first three quarters [1] - Mailande's net profit slightly decreased by 0.07% to 96 million yuan for the first three quarters [1] - Tengjing Technology's subsidiary received a sales order worth 87.61 million yuan [1] Group 3 - Hotgen Biotech's affiliate achieved positive results in Phase Ib clinical trials for the innovative drug SGC001 [1] - Zhongyan Dadi won a bid for a sports project in Beijing worth 74.04 million yuan [1] - Henghui Security's net profit decreased by 12.85% to 81.98 million yuan for the first three quarters [1] Group 4 - Xiongdi Technology's net profit increased by 71.16% to 18.38 million yuan for the first three quarters [1] - Meilixin reported a net loss of 215 million yuan for the first three quarters [1] - Haichen Pharmaceutical's net profit grew by 16.22% to 32.68 million yuan for the first three quarters [1] Group 5 - Qiaoyuan Co. reported a net profit of 181 million yuan for the first three quarters, a 40.54% increase year-on-year [1] - Fuda Co. achieved a net profit of 221 million yuan for the first three quarters, up 83.27% year-on-year [1] - Xianggang Technology's net profit surged by 186.19% to 95.47 million yuan for the first three quarters [1] Group 6 - ST Nanchuan received a restriction order from the court due to a financial dispute [1] - Changyou Technology announced the dismissal of two vice presidents [1] - Haoyuan Automotive received a project confirmation for an automatic parking system worth 576 million yuan [1] Group 7 - Jiuzhou Biotech obtained a medical device registration certificate for a diagnostic kit [1] - Shihua Machinery signed an investment intention letter for a subsidiary's capital increase [1] - Zhuhai Mian Group plans to transfer 100% equity of Gree Real Estate [1] Group 8 - Dalian Heavy Industry reported a net profit of 490 million yuan for the first three quarters, a 23.97% increase year-on-year [1] - Haimeng Data reported a net loss of 75.43 million yuan for the first three quarters [1] - Feilong Co. achieved a net profit of 287 million yuan for the first three quarters, a 7.54% increase year-on-year [1] Group 9 - Kaipu Testing reported a net profit of 57.84 million yuan for the first three quarters, a 3.34% increase year-on-year [1] - Ganyue Express signed a strategic cooperation agreement with a major energy company [1] - Tuoshan Heavy Industry's controlling shareholder plans to reduce its stake by 2.82% [1] Group 10 - Yiatong's shareholder plans to reduce its stake by 1% [1] - Weishi Electronics reported a net profit of 24.29 million yuan for the first three quarters, a 22.59% decrease year-on-year [1] - Shensi Electronics won a bid for a data space construction project worth 161 million yuan [1] Group 11 - Xiechuang Data plans to purchase server assets worth up to 4 billion yuan [1] - Shandong Express's controlling shareholder plans to transfer 7% of its shares [1] - ST Huapeng's subsidiary received a government subsidy of 4.65 million yuan [1] Group 12 - Jieqiang Equipment's shareholder plans to reduce its stake by 1% [1] - China Jushi reported a net profit of 2.568 billion yuan for the first three quarters, a 67.51% increase year-on-year [1] - ST Fanli reported a net loss of 44.78 million yuan for the first three quarters [1] Group 13 - Xiyu Tourism reported a net profit of 98.58 million yuan for the first three quarters, a 14.51% decrease year-on-year [1] - Abison reported a net profit of 185 million yuan for the first three quarters, a 57.33% increase year-on-year [1] - Huayan Precision reported a net profit of 70.76 million yuan for the first three quarters, a 31.07% increase year-on-year [1] Group 14 - Jiangling Motors reported a net profit of 74.9 million yuan for the first three quarters, a 35.76% decrease year-on-year [1]

智通财经APP讯，海辰药业(300584.SZ)发布2025年三季度报告，前三季度，公司实现营业收入4.72亿 元，同比增长30.80%。归属于上市公司股东的净利润3267.85万元，同比增长16.22%。归属于上市公司 股东的扣除非经常性损益的净利润2954.31万元，同比增长1.64%。 ...

格隆汇10月22日丨海辰药业(300584.SZ)公布三季度报告，前三季营业收入4.7亿元，同比增长30.80%， 归属于上市公司股东的净利润3267.85万元，同比增长16.22%，归属于上市公司股东的扣除非经常性损 益的净利润2954万元，同比增长1.64%。 ...

Company Overview - Haichen Pharmaceutical (SZ 300584) announced on October 22 that its fifth board meeting was held via telecommunication to review the full report for the third quarter of 2025 [1] - The company's revenue composition for the period from January to December 2024 is entirely from the pharmaceutical manufacturing sector, accounting for 100.0% [1] - As of the report, Haichen Pharmaceutical has a market capitalization of 6.7 billion yuan [1]

证券代码：300584 证券简称：海辰药业 公告编号：2025-049 南京海辰药业股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长曹于平先生召集，会议通知于 2025 年 10 月 17 日电 话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会议的 相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 10 月 22 日以通讯表决方式召开。 3、本次董事会应出席 7 人，实际出席会议人数为 7 人。 会议审议并通过如下议案： 1、审议通过《2025 年第三季度报告全文》 经审核，董事会认为编制和审核南京海辰药业股份有限公司 2025 年第三季 度报告的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公司董事会批准报出公司《2025 年第三季度报告全文》。具体内容详见公司同 日披露在中国证监会创业板指定信息披露网站巨潮资讯网的相关公 ...

Revenue and Profit - The company's revenue for Q3 2025 reached ¥162,954,321.51, representing a year-on-year increase of 31.45%[5] - Net profit attributable to shareholders was ¥3,520,760.91, up 4.15% compared to the same period last year[5] - Operating revenue increased by 30.80% to ¥471,526,892.93 compared to ¥360,497,824.16 in the same period last year, primarily due to growth in the injection of hydrochloride lanadelumab business[9] - Total operating revenue for the current period reached ¥471,526,892.93, an increase from ¥360,497,824.16 in the previous period, representing a growth of approximately 30.9%[17] - Net profit for the current period was ¥32,194,633.14, compared to ¥28,116,806.63 in the previous period, reflecting an increase of approximately 14.8%[18] - Total comprehensive income for the period attributable to the parent company was CNY 32,678,503.32, compared to CNY 28,116,806.63 in the previous period, representing an increase of approximately 15.5%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,483,375,637.55, an increase of 1.29% from the end of the previous year[5] - The company’s total assets increased to ¥1,483,375,637.55 from ¥1,464,546,955.74, marking a growth of about 1.3%[16] - The company’s total liabilities decreased to ¥410,137,814.43 from ¥426,373,270.65, a reduction of approximately 3.8%[16] - The total equity attributable to shareholders increased to ¥1,043,329,086.59 from ¥1,022,936,243.51, reflecting a growth of about 1.98%[16] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥58,486,668.79, up 33.09%[5] - Net cash flow from operating activities increased by 33.09% to ¥58,486,668.79 from ¥43,945,167.75, attributed to higher cash inflows from product sales[9] - Cash inflow from operating activities totaled CNY 477,727,059.54, compared to CNY 398,528,192.31 in the previous period, marking an increase of about 19.9%[21] - Cash outflow from operating activities was CNY 419,240,390.75, up from CNY 354,583,024.56, which is an increase of approximately 18.2%[22] - The ending balance of cash and cash equivalents was CNY 76,144,155.15, compared to CNY 38,197,993.87 in the previous period, indicating a significant increase[22] Expenses - Management expenses rose by 64.56% to ¥104,692,101.85 from ¥63,620,585.66, mainly due to the inclusion of pre-research expenses for unapproved R&D projects[9] - Research and development expenses for the current period were ¥31,204,448.18, down from ¥34,268,297.38, a decrease of about 9.5%[18] Other Financial Metrics - The basic earnings per share for the period was ¥0.0293, reflecting a 3.90% increase year-on-year[5] - Basic and diluted earnings per share increased to CNY 0.2723 from CNY 0.2343, reflecting a growth of about 16.5%[19] - The company reported a significant increase of 469.63% in other receivables, totaling ¥466,728.92, attributed to increased receivables and reserves[8] - The company reported an investment loss of ¥2,763,924.66, primarily due to investments made by the subsidiary Anqing Huichen[9] - The total deferred tax liabilities decreased by 32.40% to ¥8,436,277.90 from ¥12,480,575.90, mainly due to the reduction in deferred tax expenses recognized at the end of the previous year[9] Financing Activities - The net cash flow from financing activities decreased by 414.57% to -¥21,988,756.49 from ¥6,990,069.18, reflecting a reduction in financing loan amounts compared to the previous year[9] - Cash inflow from financing activities was CNY 203,100,000.00, down from CNY 251,100,483.33, representing a decrease of about 18.9%[22] - The company raised CNY 15,000,000.00 from minority shareholders during the financing activities[22] Other Information - The company experienced a 91.90% decrease in employee compensation payable, amounting to ¥352,240.86, due to the distribution of annual bonuses[8] - The third quarter financial report was not audited, which may impact the reliability of the reported figures[23]

格隆汇10月22日丨海辰药业(300584.SZ)在投资者互动平台表示，公司部分电解液添加剂产品已向国内 头部电解液厂商量产供货，相关进展可见公司定期报告。 ...

Market Overview - As of 14:00, the Shanghai Composite Index is at 3859.80 points, with an increase of 0.52% [1] - The total trading volume of A-shares today is 1,431.28 billion yuan [1] Technical Analysis - A total of 84 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - The stocks with the largest distance between their 5-day and 10-day moving averages include: - Yunnan Zhenye: 5-day MA is -2.45% below the 10-day MA [1] - Qiangli New Materials: 5-day MA is -2.22% below the 10-day MA [1] - Feirongda: 5-day MA is -2.14% below the 10-day MA [1] Individual Stock Performance - Yunnan Zhenye (002428): Today's change is -0.93%, with a 5-day MA of 27.71 yuan and a 10-day MA of 28.41 yuan [1] - Qiangli New Materials (300429): Today's change is +0.53%, with a 5-day MA of 13.95 yuan and a 10-day MA of 14.26 yuan [1] - Feirongda (300602): Today's change is +1.03%, with a 5-day MA of 33.00 yuan and a 10-day MA of 33.72 yuan [1] - Other notable stocks include: - Warner Pharmaceuticals (688799): Today's change is +0.43%, with a 5-day MA of 55.41 yuan [1] - Blue Ying Equipment (300293): Today's change is +0.34%, with a 5-day MA of 24.48 yuan [1] Additional Stock Data - The following stocks also show a downward trend in their 5-day moving averages compared to their 10-day moving averages: - Nanya New Materials (688519): -0.90% change, 5-day MA of 74.18 yuan [1] - Aerospace Morning Light (600501): -2.84% change, 5-day MA of 23.60 yuan [1] - Haichen Pharmaceutical (300584): +1.92% change, 5-day MA of 57.39 yuan [1]

证券日报网讯海辰药业（300584）10月16日在互动平台回答投资者提问时表示，截至10月10日，公司股 东数为22685户。 ...

10月15日消息，截止10:45，原料药板块强势，亚太药业涨停，向日葵、海辰药业、博腾股份、华海药 业、金达威等个股涨幅居前。 责任编辑：小浪快报 ...